RU2006114701A - Оптимизированная экспрессия l1 hpv45 в дрожжах - Google Patents
Оптимизированная экспрессия l1 hpv45 в дрожжах Download PDFInfo
- Publication number
- RU2006114701A RU2006114701A RU2006114701/13A RU2006114701A RU2006114701A RU 2006114701 A RU2006114701 A RU 2006114701A RU 2006114701/13 A RU2006114701/13 A RU 2006114701/13A RU 2006114701 A RU2006114701 A RU 2006114701A RU 2006114701 A RU2006114701 A RU 2006114701A
- Authority
- RU
- Russia
- Prior art keywords
- particles
- vaccine
- recombinant
- vlp particles
- yeast
- Prior art date
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims 10
- 239000002245 particle Substances 0.000 claims 16
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 9
- 229960005486 vaccine Drugs 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- 241000341655 Human papillomavirus type 16 Species 0.000 claims 2
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 claims 2
- 241000235650 Kluyveromyces marxianus Species 0.000 claims 2
- 241000235058 Komagataella pastoris Species 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 241000320412 Ogataea angusta Species 0.000 claims 2
- 241001631646 Papillomaviridae Species 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000235649 Kluyveromyces Species 0.000 claims 1
- 241001138401 Kluyveromyces lactis Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 241000235346 Schizosaccharomyces Species 0.000 claims 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Claims (25)
1. Молекула нуклеиновой кислоты, содержащая последовательность нуклеотидов, которая кодирует белок L1 HPV45, представленный SEQ ID NO:2, причем данная последовательность нуклеиновой кислоты является кодон-оптимизированной для высокоуровневой экспрессии в дрожжевой клетке.
2. Вектор, содержащий молекулу нуклеиновой кислоты по п.1.
3. Клетка-хозяин, содержащая вектор по п.2.
4. Клетка-хозяин по п.3, где клетка-хозяин выбрана из группы, состоящей из Saccharomyces cerevisiae, Hansenula polymorpha, Pichia pastoris, lactis, и Schizosaccharomyces Kluyveromyces fragilis, Kluyveromyces pombe.
5. Клетка-хозяин по п.4, где данная клетка-хозяин представляет собой Saccharomyces cerevisiae.
6. Молекула нуклеиновой кислоты по п.1, в которой последовательность нуклеотидов содержит последовательность нуклеотидов, представленную SEQ ID NO:1.
7. Вектор, содержащий молекулу нуклеиновой кислоты по п.6.
8. Клетка-хозяин, содержащая вектор по п.7.
9. Вирусоподобные частицы (VLP), образованные рекомбинантным белком L1 или рекомбинантными белками L1+L2 HPV45, где рекомбинантный белок L1 или данные рекомбинантные белки L1+L2 продуцируются в дрожжах.
10. VLP-частицы по п.9, где рекомбинантный белок L1 или рекомбинантные белки L1+L2 кодируются кодон-оптимизированной молекулой нуклеиновой кислоты L1 HPV45.
11. VLP-частицы по п.10, где кодон-оптимизированная молекула нуклеиновой кислоты состоит, в сущности, из последовательности нуклеотидов, представленной SEQ ID NO:1.
12. Способ получения VLP-частиц по п.10, включающий в себя:
(а) трансформирование дрожжей кодон-оптимизированной молекулой ДНК, кодирующей белок L1 HPV45 или белки L1+L2 HPV45;
(b) культивирование трансформиронных дрожжей в условиях, которые делают возможной экспрессию кодон-оптимизированной молекулы ДНК c получением рекомбинантного белка вируса папилломы; и
(с) выделение рекомбинантного белка вируса папилломы для получения VLP-частиц по п.10.
13. Вакцина, содержащая VLP-частицы по п.10.
14. Фармацевтические композиции, содержащие VLP-частицы по п.10.
15. Способ предотвращения HPV-заражения, предусматривающий введение млекопитающему вакцины по п.13.
16. Способ индукции иммунного ответа у животного, предусматривающий введение животному VLP-частиц по п.10.
17. Вирусоподобные частицы по п.10, где дрожжи выбраны из группы, состоящей из Saccharomyces cerevisiae, Hansenula polymorpha, Pichia pastoris, Kluyveromyces fragilis, Kluyveromyces lactis, и Schizosaccharomyces pombe.
18. Вирусоподобные частицы по п.17, где дрожжи представляют собой Saccharomyces cerevisiae.
19. Вакцина по п.13, дополнительно содержащая VLP-частицы, по меньшей мере, из одного дополнительного HPV-типа.
20. Вакцина по п.19, в которой, по меньшей мере, один дополнительный HPV-тип выбран из группы, состоящей из HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV51, HPV52, HPV55, HPV56, HPV58, HPV59, и HPV68.
21. Вакцина по п. 20, в которой, по меньшей мере, один HPV-тип включает в себя HPV16.
22. Вакцина по п. 21, дополнительно содержащая VLP-частицы HPV18.
23. Вакцина по п. 22, дополнительно содержащая VLP-частицы HPV6 и VLP-частицы HPV11.
24. Вакцина по п. 23, дополнительно содержащая VLP-частицы HPV31.
25. Вакцина по п. 22, дополнительно содержащая VLP-частицы HPV31.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50681203P | 2003-09-29 | 2003-09-29 | |
| US60/506,812 | 2003-09-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006114701A true RU2006114701A (ru) | 2007-11-10 |
| RU2360001C2 RU2360001C2 (ru) | 2009-06-27 |
Family
ID=34421558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006114701/13A RU2360001C2 (ru) | 2003-09-29 | 2004-09-24 | Оптимизированная экспрессия l1 hpv45 в дрожжах |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US7250170B2 (ru) |
| EP (1) | EP1673106B1 (ru) |
| JP (4) | JP5451960B2 (ru) |
| KR (1) | KR101165278B1 (ru) |
| CN (1) | CN1859923B (ru) |
| AR (2) | AR045804A1 (ru) |
| AT (1) | ATE435029T1 (ru) |
| AU (1) | AU2004277934B2 (ru) |
| BE (1) | BE2015C072I2 (ru) |
| BR (1) | BRPI0414845B8 (ru) |
| CA (1) | CA2539168C (ru) |
| CY (2) | CY1110525T1 (ru) |
| DE (1) | DE602004021828D1 (ru) |
| DK (1) | DK1673106T3 (ru) |
| ES (1) | ES2327530T3 (ru) |
| FR (1) | FR15C0083I2 (ru) |
| HU (1) | HUS1500063I1 (ru) |
| IL (1) | IL174458A (ru) |
| IS (1) | IS2694B (ru) |
| LT (2) | LTPA2015049I1 (ru) |
| LU (1) | LU92902I2 (ru) |
| MX (1) | MXPA06003457A (ru) |
| MY (1) | MY140664A (ru) |
| NL (1) | NL300776I2 (ru) |
| NO (3) | NO339932B1 (ru) |
| NZ (1) | NZ545834A (ru) |
| PL (1) | PL1673106T3 (ru) |
| PT (1) | PT1673106E (ru) |
| RU (1) | RU2360001C2 (ru) |
| SI (1) | SI1673106T1 (ru) |
| TW (1) | TWI350853B (ru) |
| WO (1) | WO2005032586A1 (ru) |
| ZA (1) | ZA200601961B (ru) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| US7858098B2 (en) * | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
| MY139500A (en) | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
| CA2560487C (en) * | 2004-03-24 | 2013-01-29 | Merck & Co., Inc. | Optimized expression of hpv 52 l1 in yeast |
| US7758866B2 (en) | 2004-06-16 | 2010-07-20 | Glaxosmithkline Biologicals, S.A. | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 |
| CA2604909A1 (en) | 2005-04-15 | 2006-10-26 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
| AR054259A1 (es) * | 2005-04-26 | 2007-06-13 | Glaxosmithkline Biolog Sa | Vacuna contra virus de papiloma humano (hpv) |
| US8101342B2 (en) * | 2006-08-28 | 2012-01-24 | Sungkyunkwan University Foundation For Corporate Collaboration | DNA vaccine for treating or preventing cervical cancer comprising a gene encoding HPV protein |
| CN101622008A (zh) * | 2007-03-09 | 2010-01-06 | 默克公司 | 乳头瘤病毒疫苗组合物 |
| MY162658A (en) * | 2007-11-23 | 2017-06-30 | Shanghai Zerun Biotechnology Co Ltd | Genes encoding major capsid protein l1 of human papilloma virus and use of the same |
| AU2009348078B2 (en) | 2009-06-19 | 2013-03-14 | Eyegene Inc. | Vaccine for cervical cancer |
| WO2011149897A1 (en) | 2010-05-25 | 2011-12-01 | Qiagen Gaithersburg, Inc. | Fast results hybrid capture assay and associated strategically-truncated probes |
| US8871466B2 (en) | 2011-06-15 | 2014-10-28 | Chung-Ang University Industry-Academic Cooperation Foundation | Method for enhancing the production yield of human papillomavirus L1 protein |
| KR102049988B1 (ko) | 2011-06-24 | 2019-11-28 | 머크 샤프 앤드 돔 코포레이션 | 알루미늄 아주반트를 포함하는 hpv 백신 제제 및 그의 제조 방법 |
| CN103215302B (zh) * | 2012-01-21 | 2019-01-15 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv18 l1蛋白的方法 |
| CN103361280B (zh) * | 2012-03-28 | 2018-07-24 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv11 l1蛋白的方法 |
| CN104120089B (zh) * | 2013-04-26 | 2019-09-24 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv52 l1蛋白的方法 |
| CN110423774A (zh) * | 2013-04-26 | 2019-11-08 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv58 l1蛋白的方法 |
| CN110295190A (zh) * | 2013-05-17 | 2019-10-01 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv45 l1蛋白的方法 |
| CN104513826B (zh) * | 2013-09-29 | 2020-10-20 | 上海泽润生物科技有限公司 | 人乳头瘤病毒基因,及载体,菌株,表达方法 |
| WO2015057541A1 (en) | 2013-10-16 | 2015-04-23 | Merck Sharp & Dohme Corp. | Method of obtaining thermostable dried vaccine formulations |
| JP2017528137A (ja) * | 2014-09-11 | 2017-09-28 | カディラ ヘルスケア リミティド | 卓越した免疫学的特性を有する卓越したヒトパピローマウイルス抗原及びそれを含むワクチン |
| CN106282278B (zh) * | 2015-06-29 | 2021-06-08 | 广东东阳光药业有限公司 | 一种人乳头瘤病毒l1蛋白的发酵方法 |
| CN106701798B (zh) * | 2015-08-12 | 2021-09-17 | 北京康乐卫士生物技术股份有限公司 | 45型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
| CN109750050B (zh) * | 2017-11-07 | 2023-08-18 | 上海泽润生物科技有限公司 | 重组人乳头瘤病毒45亚型蛋白表达 |
| CR20220395A (es) | 2020-02-14 | 2022-10-27 | Merck Sharp & Dome Llc | Vacuna contra hpv |
| CN112680462B (zh) * | 2020-12-29 | 2022-02-22 | 上海博唯生物科技有限公司 | 一种人乳头瘤病毒35型/hpv35型l1/l2及其制备与应用 |
| CN113073105B (zh) * | 2021-03-23 | 2023-06-13 | 重庆博唯佰泰生物制药有限公司 | 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用 |
| US20230048144A1 (en) | 2021-08-06 | 2023-02-16 | Merck Sharp & Dohme Llc | Hpv vaccine |
| CA3229064A1 (en) | 2021-08-19 | 2023-02-23 | Andrew Bett | Thermostable lipid nanoparticle and methods of use thereof |
| TW202513091A (zh) | 2023-06-09 | 2025-04-01 | 美商默沙東有限責任公司 | 用於人類乳突病毒疫苗之奈米乳液佐劑組合物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU693203B2 (en) * | 1994-05-16 | 1998-06-25 | Merck Sharp & Dohme Corp. | Papillomavirus vaccines |
| AR004464A1 (es) * | 1994-11-14 | 1998-12-16 | Merck Sharp & Dohme | Un metodo para producir una proteina de capside de papilomavirus |
| IL117459A (en) * | 1995-03-22 | 2005-11-20 | Merck & Co Inc | Dna encoding human papillomavirus type 18 |
| IL117591A0 (en) * | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
| DE69836206T2 (de) | 1997-02-07 | 2007-08-23 | Merck & Co., Inc. | Synthetische hiv gag gene |
| DE69732378D1 (de) * | 1997-05-27 | 2005-03-03 | Hanil Synthetic Fiber Co Ltd | Verfahren zur herstellung von rekombinanten eiweissen durch verwendung von hocheffizienten expressionsvektoren aus saccharomyces cerevisiae |
| CA2296067C (en) | 1997-07-09 | 2008-10-07 | The University Of Queensland | Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
| US6991795B1 (en) * | 1998-08-14 | 2006-01-31 | Merck & Co., Inc. | Protein delivery system using human papillomavirus virus-like particles |
| EP1105157B1 (en) * | 1998-08-14 | 2006-11-02 | Merck & Co., Inc. | Protein delivery system using human papillomavirus virus-like particles |
| PL347472A1 (en) * | 1998-08-14 | 2002-04-08 | Merck & Co Inc | Process for purifying human papillomavirus virus-like particles |
| DE69924007T2 (de) * | 1998-12-23 | 2006-04-06 | Merck & Co., Inc. | Neutralsierungs-assay, das humane papillomavirus-ähnliche partikel verwendet |
| PT1212358E (pt) * | 1999-08-25 | 2005-04-29 | Merck & Co Inc | Genes sinteticos de papilomavirus humano |
| US6436402B1 (en) * | 1999-10-15 | 2002-08-20 | Merck & Co., Inc. | Process for making human papillomavirus virus-like particles with improved properties |
| US7026443B1 (en) * | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
| AU7569501A (en) | 2000-07-21 | 2002-02-05 | Glaxo Group Ltd | Codon-optimized papilloma virus sequences |
| AU2003219760A1 (en) * | 2002-02-14 | 2003-09-04 | Novavax, Inc. | Optimization of gene sequences of virus-like particles for expression in insect cells |
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| MXPA05010285A (es) | 2003-03-24 | 2005-11-17 | Merck & Co Inc | Expresion optimizada de hpv 31 l1 en levadura. |
-
2004
- 2004-09-21 MY MYPI20043867A patent/MY140664A/en unknown
- 2004-09-22 AR ARP040103420A patent/AR045804A1/es active IP Right Grant
- 2004-09-23 TW TW093128883A patent/TWI350853B/zh not_active IP Right Cessation
- 2004-09-24 ES ES04788982T patent/ES2327530T3/es not_active Expired - Lifetime
- 2004-09-24 RU RU2006114701/13A patent/RU2360001C2/ru active
- 2004-09-24 KR KR1020067006044A patent/KR101165278B1/ko not_active Expired - Lifetime
- 2004-09-24 CN CN2004800281067A patent/CN1859923B/zh not_active Expired - Lifetime
- 2004-09-24 SI SI200431180T patent/SI1673106T1/sl unknown
- 2004-09-24 PL PL04788982T patent/PL1673106T3/pl unknown
- 2004-09-24 EP EP04788982A patent/EP1673106B1/en not_active Expired - Lifetime
- 2004-09-24 JP JP2006528190A patent/JP5451960B2/ja not_active Expired - Lifetime
- 2004-09-24 MX MXPA06003457A patent/MXPA06003457A/es active IP Right Grant
- 2004-09-24 DK DK04788982T patent/DK1673106T3/da active
- 2004-09-24 CA CA2539168A patent/CA2539168C/en not_active Expired - Lifetime
- 2004-09-24 AT AT04788982T patent/ATE435029T1/de active
- 2004-09-24 BR BRPI0414845A patent/BRPI0414845B8/pt not_active IP Right Cessation
- 2004-09-24 US US10/573,330 patent/US7250170B2/en not_active Expired - Lifetime
- 2004-09-24 AU AU2004277934A patent/AU2004277934B2/en active Active
- 2004-09-24 WO PCT/US2004/031326 patent/WO2005032586A1/en not_active Ceased
- 2004-09-24 NZ NZ545834A patent/NZ545834A/en not_active IP Right Cessation
- 2004-09-24 DE DE602004021828T patent/DE602004021828D1/de not_active Expired - Lifetime
- 2004-09-24 PT PT04788982T patent/PT1673106E/pt unknown
-
2006
- 2006-03-08 ZA ZA200601961A patent/ZA200601961B/en unknown
- 2006-03-20 IS IS8362A patent/IS2694B/is unknown
- 2006-03-21 IL IL174458A patent/IL174458A/en active IP Right Grant
- 2006-04-28 NO NO20061876A patent/NO339932B1/no active Protection Beyond IP Right Term
-
2007
- 2007-05-23 US US11/805,453 patent/US7482015B2/en not_active Expired - Lifetime
-
2009
- 2009-09-21 CY CY20091100973T patent/CY1110525T1/el unknown
-
2010
- 2010-07-07 AR ARP100102440A patent/AR077396A2/es not_active Application Discontinuation
-
2011
- 2011-03-02 JP JP2011045589A patent/JP2011152137A/ja active Pending
-
2014
- 2014-06-24 JP JP2014129350A patent/JP2014221052A/ja active Pending
-
2015
- 2015-11-30 NL NL300776C patent/NL300776I2/nl unknown
- 2015-12-02 HU HUS1500063C patent/HUS1500063I1/hu unknown
- 2015-12-04 FR FR15C0083C patent/FR15C0083I2/fr active Active
- 2015-12-07 CY CY2015050C patent/CY2015050I2/el unknown
- 2015-12-08 LU LU92902C patent/LU92902I2/xx unknown
- 2015-12-08 LT LTPA2015049D patent/LTPA2015049I1/lt unknown
- 2015-12-08 LT LTPA2015049C patent/LTC1673106I2/lt unknown
- 2015-12-09 BE BE2015C072C patent/BE2015C072I2/nl unknown
-
2016
- 2016-02-04 JP JP2016019712A patent/JP2016136947A/ja active Pending
-
2017
- 2017-04-05 NO NO2017012C patent/NO2017012I1/no unknown
-
2022
- 2022-11-30 NO NO2022051C patent/NO2022051I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006114701A (ru) | Оптимизированная экспрессия l1 hpv45 в дрожжах | |
| RU2006120402A (ru) | Оптимизированная экспрессия hpv 58 l1 в дрожжах | |
| RU2005132603A (ru) | Оптимизированная экспрессия hpv 31 l1 в дрожжах | |
| RU2006137363A (ru) | Оптимизированная экспрессия hpv 52 l1 в дрожжах | |
| JP2007507207A5 (ru) | ||
| Roden et al. | Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope | |
| JP2012010713A5 (ru) | ||
| JP7805920B2 (ja) | キメラパピローマウイルスｌ１タンパク質 | |
| RU97110164A (ru) | Очищенные белки вируса папилломы | |
| CN116041444A (zh) | 人乳头瘤病毒hpv39 l1蛋白的表达和类病毒样颗粒及其制备方法 | |
| CN114127098B (zh) | 嵌合的人乳头瘤病毒51型l1蛋白 | |
| CN1293093C (zh) | 乳头瘤病毒衣壳蛋白的原核制备和应用 | |
| JP7791078B2 (ja) | ヒトパピローマウイルスに対する多価免疫原性組成物 | |
| CA2339324A1 (en) | Protein delivery system using human papillomavirus virus-like particles | |
| CN116102627A (zh) | 人乳头瘤病毒hpv35 l1蛋白的表达和类病毒样颗粒及其制备方法 | |
| CN114127127B (zh) | 嵌合的人乳头瘤病毒35型l1蛋白 | |
| CN114127100B (zh) | 嵌合的人乳头瘤病毒39型l1蛋白 | |
| CN114127097B (zh) | 嵌合的人乳头瘤病毒56型l1蛋白 | |
| Webb et al. | Cervical cancer-causing human papillomaviruses have an alternative initiation site for the L1 protein | |
| CA2340422A1 (en) | Method for producing yeast expressed hpv types 6 and 16 capsid proteins | |
| CN114127095B (zh) | 嵌合的人乳头瘤病毒11型l1蛋白 | |
| TH72490B (th) | การแสดงออกที่ถูกทำให้เหมาะสมของ hpv 45l1 ในยีสต์ | |
| TH82139A (th) | การแสดงออกที่ถูกทำให้เหมาะสมของ hpv 45l1 ในยีสต์ | |
| TH66992B (th) | การปรับแต่งการแสดงออกของ hpv58 l1 ในยีสต์ให้เหมาะสม | |
| TH74110A (th) | การปรับแต่งการแสดงออกของ hpv58 l1 ในยีสต์ให้เหมาะสม |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Correction of name of patent owner | ||
| PC43 | Official registration of the transfer of the exclusive right without contract for inventions |
Effective date: 20130530 |
|
| PD4A | Correction of name of patent owner |